Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Adenocarcinoma × paricalcitol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 7 Unspecified Adult Solid Tumor, Protocol Specific 1 Resectable Pancreatic Carcinoma 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Ductal Adenocarcinoma 1 Neoplasms, Plasma Cell 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia 1 Breast Neoplasms 1 Anemia, Refractory, with Excess of Blasts 1 Anemia, Refractory 1 Adenocarcinoma of the Pancreas 1 Adenocarcinoma 1

Interventions

Oxaliplatin 42 Gemcitabine 41 Fluorouracil 37 Capecitabine 29 pembrolizumab 28 Leucovorin 26 Docetaxel 25 Cisplatin 24 Paclitaxel 21 Carboplatin 18 Bevacizumab 17 Irinotecan 16 130-nm albumin-bound paclitaxel 16 Pemetrexed 15 Radiotherapy 13 Albumin-Bound Paclitaxel 13 Nivolumab 12 Cyclophosphamide 10 Ramucirumab 9 Trastuzumab 7 Radiosurgery 7 cemiplimab 6 Taxes 6 Erlotinib Hydrochloride 6 Drug Therapy 6 zolbetuximab 5 trastuzumab deruxtecan 5 durvalumab 5 Sorafenib 5 S 1 (combination) 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03415854 2023-12-15

NABPLAGEMD

HonorHealth Research Institute

Phase 2 Completed

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡